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A B S T R A C T
Background
Venous thromboembolic disease (TED), although rare, is a major cause of maternal mortality and morbidity, hence methods of
prophylaxis are often used for women at risk. This may include women delivered by caesarean section, those with a personal or family
history of TED and women with inherited or acquired thrombophilias (conditions that predispose people to thrombosis). Many
methods of prophylaxis carry a risk of side effects, and as the risk of TED is low, it is possible that the benefits of thromboprophylaxis
may be outweighed by harm. Current guidelines for clinical practice are based on expert opinion only, rather than high quality evidence
from randomised trials.
Objectives
To determine the effects of thromboprophylaxis in women who are pregnant or have recently delivered and are at increased risk of
TED on the incidence of venous TED and side effects of treatment.
Search strategy
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (May 2009).
Selection criteria
Randomised trials comparing one method of thromboprophylaxis with placebo or no treatment, and randomised trials comparing two
(or more) methods of thromboprophylaxis.
Data collection and analysis
Two review authors extracted data independently and resolved any discrepancies by discussion.
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Main results
Sixteen trials met the inclusion criteria but only 13 trials, involving 1774 women, examining a range of methods of thromboprophylaxis,
contributed data for the outcomes of interest. Four of them compared methods of antenatal prophylaxis: low molecular weight heparin
(LMWH) versus unfractionated heparin (UFH) (two studies), and heparin versus no treatment (two studies). Eight studies assessed
postnatal prophylaxis after caesarean section; one compared hydroxyethyl starch with unfractionated heparin; four compared heparin
with placebo; and the other three compared UFH with LMWH. One study examined prophylaxis in the postnatal period.
The small number of statistically significant findings in this review are largely derived from trials which are not of high methodological
quality. It was not possible to assess the effects of any of these interventions on most outcomes, and especially on rare outcomes such
as death, TED and osteoporosis, because of small sample sizes and the small number of trials making the same comparisons.There was
some evidence of side effects associated with thromboprophylaxis.
Authors’ conclusions
There is insufficient evidence on which to base recommendations for thromboprophylaxis during pregnancy and the early postnatal
period. Large scale randomised trials of currently-used interventions should be conducted.
P L A I N L A N G U A G E S U M M A R Y
Preventing deep vein clots or thrombosis (DVT) in pregnancy and after the birth
Some women are at risk of forming blood clots in a deep vein during pregnancy, after a caesarean birth, or during the first few weeks after
childbirth. If part of the clot breaks off and lodges in a blood vessel in the lungs, it can be life-threatening. Preventive treatments include
blood-thinning drugs to prevent clots, support stockings, and exercise soon after the birth to keep circulation moving. However, some
drugs might cause problems such as increased blood loss after the birth. Drugs used include heparin, low molecular weight heparin
and aspirin. We included 16 randomised controlled studies in the review but only 13 trials with 1774 women contributed data for
the outcomes of interest. We did not find enough evidence from the trials to be sure about the effects of these different preventive
treatments.This means there is not enough evidence to show which are the best ways to prevent deep vein thrombosis (DVT) during
or following pregnancy, or after a caesarean birth.
B A C K G R O U N D
Venous thromboembolic disease (TED) occurs when a blood clot
forms in a deep vein, usually in a leg, forming a deep venous
thrombosis (DVT), which may cause pain and swelling. This is
very rarely fatal, but if part of the clot breaks off it may be car-
ried to the lungs by the circulatory system and block blood ves-
sels there, resulting in a pulmonary embolism. This is more seri-
ous, and can cause chest pain, shortness of breath, haemoptysis
(coughing blood) and, if large, severe hypoxia (oxygen depriva-
tion) and collapse, which can be fatal. TED is the leading cause
of maternal mortality in developed countries (Atrash 1990; Dept
of Health 1998; Högberg 1994; Lewis 2004), and most of the
maternal deaths caused by it are due to pulmonary embolism. As
well as causing maternal death, TED can cause serious long-term
maternal morbidity (Lindhagen 1986), including venous insuffi-
ciency, often manifesting as a painful and sometimes ulcerating
leg, due to the compromised blood flow to the limb.
Alterations to the clotting system during pregnancy increase the
risk of a thromboembolic event (DVT or pulmonary embolism);
the risk is even greater in the in the early postnatal period especially
in those women undergoing caesarean section (CS). A recent case
control study reported that compared with non-pregnant women,
the risk of venous thromboembolism (VTE) was increased five-
fold during pregnancy (especially during the third trimester), and
by 60-fold during the first three months after the birth (Pomp
2008).
Although the risk of TED is increased during pregnancy and the
immediate postnatal period, it is still relatively rare.One of the best
estimates of its incidence is from a Swedish study (Lindqvist 1999),
which linked maternity and hospital admission data, and there-
fore, avoided the problem of earlier studies where the incidence
of TED may have been underestimated because some events were
not recorded as pregnancy-related. The incidence in this study
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was 0.13%, compared with other figures of 0.055% (Rutherford
1991), 0.085% (Andersen 1998), 0.06% (Gherman 1999) and
0.11% (Macklon 1996). In a UK case control study the overall
risk of TED was 0.085%, but there was a much higher risk of
events in the postnatal period following caesarean delivery. In this
study, the risk in the antenatal period was estimated as 0.028%
compared with 0.18% following CS (Simpson 2001). All of these
figures relate to all pregnancies rather than to any particular group
of women at risk. The variability in the estimates is probably due
to differences in the reliability of the methods of diagnosis used, as
well as differences between the populations in their risk factors and
use of thromboprophylaxis. A study examining trends over time
suggests that the incidence of TED during pregnancy remained
fairly constant between 1966 and 1995, while the incidence in PE
during the postnatal period decreased (Heit 2005).
Some groups ofwomenhave a higher risk of developingTED in as-
sociation with pregnancy. Specific risk factors that have been iden-
tified include operative delivery; having had one or more previous
episodes of TED; a family history of TED; having an inherited
or acquired thrombophilia (a condition that predisposes people to
developing thromboses); obesity; greater maternal age; higher par-
ity and prolonged immobilisation (Alfirevic 2002; Barbour 1997;
Larciprete 2007; Simpson 2001). The size of the increases in risk
attributable to these factors has generally been poorly quantified.
For thrombophilias the risks of a thromboembolic event in asso-
ciation with pregnancy have been estimated, and range from 5%
to 33% depending on the nature of the thrombophilia (Conard
1990; Friederich 1996; Pomp 2008). For women who have had a
previous thrombosis in pregnancy, the risk of TED increases con-
siderably in subsequent pregnancies if antenatal thromboprophy-
laxis is not used (Brill-Edwards 2000; De Stefano 2006).
Women who have particular risk factors for the development of
TED are often given thromboprophylaxis during the antenatal or
postnatal period or both (Connolly 2003; Dargaud 2005; Taylor
2000). Both pharmacological methods and non-pharmacological
methods of thromboprophylaxis have been used. Pharmacologi-
cal methods use anticoagulant drugs (heparin, warfarin, aspirin
and hydroxyethyl starch (HES)) that help to prevent clotting of
the blood. Non-pharmacological methods (stockings, pneumatic
compression, early mobilisation and surveillance) aim to keep the
blood moving in the lower limbs, thus helping to prevent forma-
tion of clots.
There has been debate about whether thromboprophylaxis is ben-
eficial and cost effective; routine screening of all pregnant women
to identify women with thrombophilias, for example, has not
been recommended, and antenatal prophylaxis for all women
with known thrombophilias remains controversial (Brenner 2003;
Middeldorp 2003; Wu 2005). Pharmacological methods may
cause side effects that are sufficiently severe or common to out-
weigh the benefits of thromboprophylaxis. Warfarin is known to
cause congenital abnormalities (Hall 1980) and it is, therefore,
rarely used in the first trimester or in the last few weeks of preg-
nancy. Heparin does not cross the placenta and is safe for the fe-
tus, and therefore, is generally used for antenatal therapy. How-
ever, it can cause side effects for the mother (Nelson-Piercy 1997);
there is a risk of symptomatic osteoporosis (loss of bone density,
leading to fractures), thrombocytopenia (low platelets), bleeding
and allergic reactions. When used after caesarean section, heparin
may increase the frequency of bleeding and wound complications.
Originally, unfractionated heparin (UFH) was used, but this has
now been largely superseded, at least for use in pregnancy and
postnatally, by low molecular weight heparins (LMWH). These
have the advantage that they often need to be given only once
daily and laboratory monitoring may not be required rather than
needing more complex titration regimens requiring repeated lab-
oratory blood monitoring. In addition, LMWHs are thought to
be associated with a lower risk of side effects.
Both heparin and warfarin are used for postnatal thromboprophy-
laxis and are safe for mothers who are breastfeeding (Letsky 1997;
Orme 1977).
Low dose (60 mg to 75 mg) aspirin has been widely used in preg-
nancy to try to prevent the development of pre-eclampsia (Knight
2001). Aspirin is usually well tolerated and has few side effects,
and its use for thromboprophylaxis in orthopaedic surgery (PEP
Trial 2000) suggests that it may have a role to play in the preven-
tion of TED in pregnancy.
HES was used for thromboprophylaxis in the past, and is used in
one of the trials included in this review, but it is no longer used
because of the risk of anaphylaxis (Paull 1987).
The duration of prophylaxis varies depending on the risk factor.
Women who have had a previous episode of TED may receive
long-term antenatal prophylaxis as well as prolonged postnatal
prophylaxis, while women undergoing delivery by CSmay receive
only postnatal prophylaxis for a few days.
O B J E C T I V E S
To determine the effects of thromboprophylaxis during pregnancy
and the early postnatal period inwomen at increased risk of venous
TED on the incidence of venous TED and side effects.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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Randomised controlled trials (RCTs) comparing any intervention
that may prevent TED with placebo or with no treatment, or
RCTs comparing any two or more interventions. We did not in-
clude quasi-randomised studies (i.e. those that used non-random
methods of allocating participants to groups). We did not include
studies reported only as abstracts in analyses but as studies await-
ing assessment, pending full publication of their results.
Types of participants
Women who were pregnant or had delivered in the previous six
weeks and were at increased risk of TED. This includes women
who were delivered by caesarean section, had previously had TED,
had an acquired or inherited thrombophilia, and other risk factors
for TED. We did not include women with artificial heart valves.
This is one of a series of Cochrane reviews looking at women at in-
creased risk of adverse outcomes in pregnancy. A related Cochrane
review specifically focuses on the role of heparin for pregnant
women with known thrombophilias to prevent adverse pregnancy
outcomes (Walker 2003). Thromboprophylaxis has also been used
to prevent miscarriage in women with recurrent pregnancy loss.
Two related Cochrane reviews examine the effects of antenatal
thromboprophylaxis on pregnancy loss on women with or with-
out known thrombophilias (Empson 2005; Kaandorp 2009). To
avoid duplication, the focus of this review is on the prevention of
venous thromboembolic events in pregnancy and the postpartum
period, and we have not, therefore, included studies specifically
examining the prevention of pre-eclampsia, miscarriage or other
adverse pregnancy outcomes.
Types of interventions
We considered RCTs of any intervention that may reduce TED
eligible. This included the following:
1. Pharmacological interventions
• UFH;
• LMWH;
• warfarin;
• aspirin;
• HES.
2. Non-pharmacological interventions
• Stockings;
• pneumatic compression (intermittent compression of the
calves during surgery);
• early mobilisation;
• surveillance (screening for asymptomatic thromboembolic
events to prevent symptomatic deep venous thrombosis or
pulmonary embolism).
Types of outcome measures
Primary outcomes
1. Maternal death;
2. symptomatic thromboembolic events;
3. symptomatic pulmonary embolism;
4. symptomatic deep venous thrombosis (DVT).
Secondary outcomes
5. Asymptomatic thromboembolic events (detected by screening);
6. blood transfusion;
7. bleeding episodes;
8. serious wound complications (wound infection requiring an-
tibiotics, dehiscence, resuturing);
9. side effects sufficient to stop treatment;
10. side effects not sufficient to stop treatment;
11. symptomatic osteoporosis (for studies involving the use of
antenatal heparin);
12. fetal loss (for studies involving the use of antenatal heparin or
aspirin);
13. thrombocytopenia (for studies involving the use of antenatal
heparin);
14. fetal anomalies (for studies involving the use of antenatal hep-
arin or aspirin).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (May
2009).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major
conferences;
4. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL and MEDLINE,
the list of handsearched journals and conference proceedings, and
the list of journals reviewed via the current awareness service can
be found in the ‘Specialized Register’ section within the edito-
rial information about the Cochrane Pregnancy and Childbirth
Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
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We did not apply any language restrictions.
Data collection and analysis
Selection of studies
Two review authors independently assessed for inclusion all the
potential studies identified by the search strategy. We resolved
disagreement through discussion.
Data extraction and management
Two authors extracted data independently using a data collection
form developed for the review. We resolved discrepancies by re-
ferring to a third author. We entered data into Review Manager
software (RevMan 2008), and checked them for accuracy.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias for
each study using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2008).We resolved
disagreements by discussion or by reference to a third author.
(1) Sequence generation
We assessed the methods as:
• adequate (e.g. random number table; computer random
number generator);
• inadequate (odd or even date of birth; hospital or clinic
record number); or
• unclear.
We excluded studies with inadequate random sequence generation
(i.e. quasi-randomised).
(2) Allocation concealment
We recorded the method used to conceal the allocation sequence
before randomisation for each trial. We assessed methods as ade-
quate if the next allocation in the sequence could not be discovered
before randomisation, and could not be changed once allocated.
We assessed the methods as:
• adequate (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• inadequate (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear.
(3) Blinding
We recorded for each study themethods used, if any, to blind study
participants and personnel from knowledge of which intervention
each participant received, along with any information relating to
whether the intended blinding was effective. Where blinding was
not possible, we assessed whether the lack of blinding was likely
to have introduced bias.
The methods were assessed as:
• adequate, inadequate, not possible or unclear for
participants;
• adequate, inadequate, not possible or unclear for personnel;
• adequate, inadequate, not possible or unclear for outcome
assessors.
(4) Incomplete outcome data
We recorded the completeness of outcome data in each study for
each main outcome including attrition and exclusions from the
analysis.
(5) Other sources of bias
We assessed the possibility of other sources of bias, including se-
lective reporting of outcomes, and reported any evidence of prob-
lems.
Measures of treatment effect
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2008). In the absence of heterogeneity we planned
to use fixed-effect meta-analysis. For dichotomous data, we have
presented results as summary risk ratio with 95% confidence in-
tervals.We used themean difference for the analysis of continuous
outcomes for outcomes measured in the same way between trials,
and the standardised mean difference for trials that measured the
same outcome using different methods.
We have analysed studies addressing different comparisons sep-
arately. We have summarised results under three main headings,
each of which included several different comparisons between
methods of thromboprophylaxis:
1. antenatal or antenatal + postnatal or antenatal +
intrapartum thromboprophylaxis;
2. postnatal or intrapartum + postnatal thromboprophylaxis;
3. thromboprophylaxis given during or after caesarean section.
Unit of analysis issues
We did not identify any cluster-randomised trials. Crossover trials
are an inappropriate design and we have not included them.
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Dealing with missing data
For all outcomes, we conducted analyses as far as possible on an
intention-to-treat basis, i.e. we attempted to include all partici-
pants randomised in their allocated group. If participants were
omitted or analysed in the incorrect group, we included them in
the analyses in the correct group if the report contained sufficient
information to allow this. We omitted participants with missing
outcome data from the analysis; i.e. we did not impute outcomes
for participants with missing data. In all analyses the denominator
was the number randomised minus the number with missing data.
Assessment of heterogeneity
We assessed heterogeneity using the I² and T² statistics. We
planned to explore heterogeneity using the pre-specified subgroup
analyses, but there were insufficient trials in any comparison to
make this feasible. For outcomes where we identified considerable
or high levels of heterogeneity (I² > 30%) we planned either to
carry out a random-effects analysis and to present this result, or not
to pool results from studies in meta-analysis. For many outcomes
data were available from only a single study and heterogeneity was
not an issue.
Subgroup analysis and investigation of heterogeneity
We pre-specified one subgroup analysis: stratifying by risk factors
for TED, i.e. previous venous TED; family history of TED; inher-
ited or acquired thrombophilia; emergency or elective caesarean
section with or without other risk factors; or other risk factors.
However, we were unable to conduct any subgroup analyses due
to lack of data. We will include these analyses in future versions
of the review if the necessary data become available.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
We considered 38 studies for inclusion (described in 53 reports
identified by the search). Of these, we assessed 16 as eligible for
inclusion and excluded 16. Four studies are awaiting further as-
sessment because results were reported in abstracts only and we are
awaiting publication of the full study report (De Veciana 2001;
Dittmer 1991; Hamersley 1998; Kamin 2008). Two studies are
ongoing and full results have not yet been published; we hope to
include results from these trials in the next update of the review
(STOP CLOT; TIPPS).
Two of the studies which were otherwise eligible for inclusion did
not report on any of the review’s primary or secondary outcomes
but focused instead on the laboratory results of blood samples
taken fromwomen receiving thromboprophylactic agents (Ellison
2001;Harenberg 1993).More information on these studies is pro-
vided in the Characteristics of included studies tables, but these
studies have not contributed data to the analyses in the review.One
further study, otherwise eligible for inclusion (Cornette 2002) ex-
amined the timing of LMW heparin with the first dose adminis-
tered during versus after caesarean; again we have included details
of this study in the Characteristics of included studies tables and
have provided a brief summary of results, but we have not included
it in any treatment comparisons in the review. In the results sec-
tion below we will describe findings for those 13 included studies
which contributed data to the review.
Included studies
Although 16 studies met the eligibility criteria for inclusion, only
13 studies contributed data for the outcomes of interest.
Eight of the studies evaluated thromboprophylaxis after (or dur-
ing and after) caesarean section, but there was a range of dif-
ferent comparisons; two studies compared LMWH with placebo
(Burrows 2001; Gates 2004a;), one compared UFH with placebo
(Hill 1988); one UFH with physiotherapy compared with phys-
iotherapy alone (Welti 1981); three LMWH with UFH (Gibson
1998; Heilmann 2007; Krauss 1994), and one UFH and HES
with placebo (Heilmann 1991).
Four studies assessed antenatal, or antenatal and postnatal, throm-
boprophylaxis. Two studies compared LMWHwith UFH (Casele
2006; Pettila 1999); one compared LMWH with placebo (Gates
2004b); and one compared UFH with no treatment in the ante-
natal period (Howell 1983).
Finally, one study focused on the postnatal period alone, with
UFH compared with no treatment (Segal 1975).
Excluded studies
We excluded 16 studies. Several of the studies that may other-
wise have been eligible were excluded as their primary focus was,
for example, on the prevention of recurrent miscarriage and not
on the prevention of TED; they had no information on the re-
view’s outcomes relating to TED and, indeed, may have explic-
itly excluded women known to be at high risk of thromboem-
bolism (Badawy 2008; Brenner 2005; Chistolini 2006; De Vries
2005; Dendrinos 2007;Middeldorp 2005; Rey 2009; Stephenson
2004; Thaler 2004; Tulppala 1997). (Related Cochrane reviews
specifically examine the issue of prevention of recurrent miscar-
riage (Empson 2005; Kaandorp 2009).) We excluded four studies
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because they did not use random allocation of women to groups
(Blomback 1998; Kutteh 1996a; Kutteh 1996b; Noble 2005).
Risk of bias in included studies
Most of the included studies were not of high methodological
quality. Many of the reports did not include information on the
methods of randomisation, blinding, baseline characteristics or
non-trial treatments received by the groups being compared.
Allocation
Generation of the randomisation sequence was adequate in four
trials (Casele 2006; Gates 2004a; Gates 2004b; Pettila 1999) and
unclear in 10 trials (Burrows 2001; Cornette 2002; Gibson 1998;
Heilmann 2007;Heilmann 1991;Hill 1988;Howell 1983; Krauss
1994; Segal 1975; Welti 1981). Methods of sequence generation
reported included: random numbers table in one study (Casele
2006) a central telephone randomisation service in two studies
(Gates 2004a;Gates 2004b), and a computer generated list (Pettila
1999). Methods of allocation concealment included using pre-
prepared treatment packs dispensed by hospital pharmacy depart-
ments in four studies (Burrows 2001; Gates 2004a; Gates 2004b;
Hill 1988), and sealed opaque envelopes in two studies (Howell
1983; Pettila 1999).
Blinding
Blinding was poorly reported in many of the included studies, and
was either inadequate or unfeasible in the rest. Only three studies
reported adequate attempts to blind patients, clinicians and/or
outcome assessors.
Only five of the 16 trials included a placebo control (Burrows
2001; Gates 2004a; Gates 2004b; Heilmann 1991; Hill 1988)
and one of these (Heilmann 1991) involved the use of HES, an
intervention no longer used for thromboprophylaxis (Paull 1987).
Most of the trials without a placebo did not blind patients, care-
givers or outcomes assessors, and in the remainder blinding was
unclear. As the treatments were markedly different for the inter-
vention and control groups in these trials, it can be assumed that
there was no blinding of participants and clinicians.
Incomplete outcome data
In 10 trials there were no losses to follow up reported, although
two of these trials (Gibson 1998; Krauss 1994) did not specify
whether any women were excluded from the analysis. We have
assumed that data were recorded for all women randomised, and
while two further studies appeared to have no losses to follow up
(Segal 1975; Welti 1981) both reported very little methodological
detail. Two trials stated that some women who were randomised
were excluded from the analysis. In one trial two women were
excluded because of withdrawal of consent (Pettila 1999), and no
data were available for these individuals. In the other trial (Howell
1983) the number of exclusions varied between the tables in the
original paper, but it was possible from the text to establish the
outcomes for all randomised women. In one study (Casele 2006)
22 of 120 (18%) women were lost to follow up; however, data were
available for some outcomes. As a result, all womenwere accounted
for in some analyses, but not for the main study outcome (bone
mass of the proximal femur), and denominators were not always
clear.
Other potential sources of bias
In general the sample sizes of the trials were small. The three largest
trials recruited 580women (Welti 1981), 220women (Segal 1975)
and 207 women (Heilmann 1991). Sample sizes of this order are
inadequate to detect any difference in the incidence of rare out-
comes such as thromboembolic events. This is particularly true for
trials comparing two thromboprophylactic regimens, rather than
comparing prophylaxis with placebo or no treatment, because the
difference expected between two methods of prophylaxis is likely
to be much smaller than that between prophylaxis and placebo or
no treatment. Meta-analysis could not greatly increase the power
of individual comparisons because of the variety of different treat-
ments being compared in different patient populations.
Therewere too few studies contributingdata to allowus to examine
possible publication bias.
The assessments of risk of bias in the included studies are set out
in Figure 1 and Figure 2.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Effects of interventions
Prophylaxis for venous TED: 13 studies with 1774
women
Antenatal prophylaxis
Primary outcomes
LMWH or UFH versus placebo : two studies (Gates 2004b;
Howell 1983) with a total of 56 women compared thrombopro-
phylaxis with heparin and placebo, and for most outcomes only
one of the studies contributed data to the analyses. Neither study
reported whether or not there was any maternal mortality. There
was no statistically significant evidence of any difference between
groups in the number of symptomatic thromboembolic events; no
women in the heparin group had events compared with two in the
placebo group (n = 28) (Analysis 1.2; Analysis 1.3; Analysis 1.4).
LMWH versus UFH : two studies (Casele 2006; Pettila 1999)
with 178 women examined prophylaxis with LMWH compared
with UFH.While there were more symptomatic thromboembolic
events in the UFH group, studies did not have sufficient power
to detect statistically significant differences between groups (risk
ratio (RR) 0.47, 95% confidence interval (CI) 0.09 to 2.49).
Secondary outcomes
LMWH or UFH versus placebo : for several outcomes there were
no events reported, and there was no evidence of any signifi-
cant difference between treatment and control groups for any sec-
ondary review outcomes including bleeding episodes, blood trans-
fusion, wound complications, symptomatic osteoporosis, fetal loss
or thrombocytopenia (see Analysis 1.5 to Analysis 1.14).
LMWH versus UFH : for antenatal prophylaxis, LMWH may
have an advantage over UFH in terms of bleeding episodes; how-
ever, data for this outcome were derived from only two studies
(Casele 2006; Pettila 1999) and may be at high risk of bias. The
rates of bleeding episodes in these two studies were very different,
and when we pooled data in meta-analysis there was very high
heterogeneity (I² = 81%, T² = 2.81 and in the Chi2 test for hetero-
geneity P = 0.02). In view of such high heterogeneity we decided
not to pool data. In theCasele 2006 study, 4/60 in the LMWHand
1/57 in the UFH group were reported to have bleeding episodes (a
statistically non-significant difference). In the Pettila 1999 study,
the number of women reported to have bleeding episodes was
high in both groups (it was not clear what exactly was measured;
the authors refer to “bleeding complications” of which only two
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were “serious and required blood transfusions”). In this study, 9/50
women in the LMWH group and 35/55 in the UFH group were
reported to have bleeding. This difference, favouring LMWH, is
statistically significant but needs to be interpreted with caution.
This was an unblinded study with what could be considered as an
extremely high rate of bleeding episodes. The lack of blinding and
knowledge of treatment allocation may have influenced clinicians’
judgements about bleeding.
For other secondary outcomes including rates of blood transfusion
(Analysis 2.6), side effects sufficient to stop treatment (Analysis
2.9), symptomatic osteoporosis (Analysis 2.11) and thrombocy-
topenia (Analysis 2.13), there was no evidence of a clinically im-
portant difference between groups. Rates of fetal loss were rela-
tively high in the studies included in this comparison, with the
loss of 5/110 in the LMWH group and 8/112 in the UFH group;
but there was no significant evidence of a difference between treat-
ment groups (RR 0.61, 95% CI 0.21 to 1.77).
Prophylaxis for women undergoing caesarean section
Primary outcomes
LMWH or UFH versus placebo: four studies with 830 women
contributed data to this comparison (Burrows 2001; Gates 2004a;
Hill 1988; Welti 1981). There was no evidence of a difference be-
tween groups for symptomatic thromboembolic events (RR 1.30,
95% CI 0.39 to 4.27) with similar numbers of women in each
group experiencing DVT or PE.
LMWH versus UFH : we included three studies with 217 women
in this comparison (Gibson 1998; Heilmann 2007; Krauss 1994);
overall, there was one symptomatic thromboembolic event (one
women with a DVT), and no significant evidence of a difference
between groups (RR 0.33, 95% CI 0.01 to 7.99).
HES versus UFH : the study included in this comparison did not
report results for symptomatic thromboembolic events (Heilmann
1991).
Secondary outcomes
LMWH or UFH versus placebo: for most secondary review out-
comes including blood transfusion (Analysis 3.6), wound com-
plications (Analysis 3.8), and side effects (Analysis 3.9; Analysis
3.10) there was no statistically significant evidence of any differ-
ences between groups. There was some evidence that women re-
ceiving heparin were more likely to experience bleeding episodes
compared to women receiving placebo or no treatment. In all, 46
of the 380 women in the heparin group had bleeding compared
with 10 of the 416 controls (RR 5.15, 95% CI 2.64 to 10.05).
LMWH versus UFH: studies included in this comparison did not
report results for any of the review’s secondary outcomes, except
authors of one study reported that there were no bleeding episodes
amongst women in either group (Gibson 1998).
HES versus UFH : there was no significant evidence of differences
between groups for blood transfusion, bleeding episodes or wound
complications (Analysis 5.6; Analysis 5.7; Analysis 5.8); results
were not reported for other secondary outcomes.
Postnatal prophylaxis
UFH versus no treatment: one study (Segal 1975) examined post-
natal prophylaxis and there was no significant difference between
groups for symptomatic VTE events (Analysis 6.1) and no results
were reported for any of the review’s secondary outcomes.
D I S C U S S I O N
Summary of main results
Overall, few statistically significant differences for any comparison
were detected in the included studies. In particular we were unable
to detect any statistically significant difference in any of the four
primary outcomes of the review.
Maternal deaths were not reported in any of the included studies
and symptomatic thromboembolic events were not reported by
every included study, so that for many comparisons only one study
contributed data to the analyses. As a consequence, given the small
number of included studies and their relatively small sample sizes,
most analyses lacked the power to detect differences in these rare
outcomes even if they did exist.
For secondary outcomes, most of the included studies did not pro-
vide data, and where they did, there were few statistically signifi-
cant findings. Some results appear to show differences between the
groups. For antenatal prophylaxis, LMWH seems to be associated
with fewer bleeding episodes following treatment compared with
UFH. However, results were derived from two small studies; there
were high rates of bleeding reported in one of them and the lack
of blinding in this study may mean that it is at high risk of bias
(Pettila 1999). Further, it is not clear how bleeding was defined
in this trial. For prophylaxis for women undergoing caesarean sec-
tion there was some evidence (from nearly 800 women) that, com-
pared with placebo control, women receiving heparin (either low
molecular weight or unfractionated) had more bleeding episodes
(RR 5.15, 95% CI 2.64 to 10.05).
Overall, in view of the small number of studies included, the num-
ber of different comparisons, and the generally small size of trials,
there is insufficient evidence of the benefits or harm associated
with thromboprophylaxis.
Overall completeness and applicability of
evidence
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As already noted, there is a lack of evidence about key indica-
tors of thromboprophylaxis benefit and harm, in particular mater-
nal mortality. However, we cannot assume that because maternal
deaths were not reported none occurred. There was a general lack
of information about the performance of thromboprophylactic
agents in regard to other important secondary outcomes such as
asymptomatic thromboembolic events (which may be related to
rates of symptomatic events) and bleeding complications.
None of the included studies focused on mechanical methods
of prophylaxis (compression stockings or intermittent pneumatic
compression devices). Furthermore,many of the studies were quite
dated and included thromboprophylaxis methods which are no
longer used (such as HES) or are not used as frequently in current
thromboprophylactic practice (such as the use of UFH rather than
LMWH).
The focus of this review was on the prevention of venous TED
in pregnancy and the postpartum period; further evidence on the
use of heparin and other thromboprophylactic drugs on the pre-
vention of miscarriage and other pregnancy outcomes are exam-
ined in related Cochrane reviews (Empson 2005; Kaandorp 2009;
Walker 2003).
Quality of the evidence
The small number of statistically significant findings in this review
are largely derived from trialswhich are not of highmethodological
quality. Hence, there is a strong possibility that theymay be caused
by bias or chance. These results need to be confirmed by larger
studies before they can be regarded as reliable. Furthermore, these
trials were too small to assess the effects of their interventions on
other outcomes such as death and thromboembolic events. It is
therefore unsafe to conclude that the interventions that appear
superior are in fact to be preferred, as they may have important
undetected effects on other outcomes.
Agreements and disagreements with other
studies or reviews
Related Cochrane reviews examine pharmacological and non-
pharmacological means of thromboprophylaxis in a range of pa-
tient groups including those with chronic illness or following
surgery (e.g. Alikhan 2009; Kakkos 2008; Ramos 2008; Testroote
2008). In a review focusing on thromboprophylaxis in general
medical patients, Alikhan 2009 et al suggest that both LMWH
andUFHmay reduce risk of thromboembolism, but are associated
with increased risk of both minor and major bleeding episodes;
this increased risk of haemorrhage was less with LMWH. How-
ever, reviews which examine outcomes in non-pregnant groups
at risk of thromboembolism may not be relevant during preg-
nancy when the physiological mechanisms controlling blood co-
agulation are altered, and the risks of TED and the side effects of
thromboprophylaxis may be different. Further, during pregnancy
the risk to the developing fetus from pharmacological methods of
thromboprophylaxis is an important consideration in the choice
of method.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient evidence available from RCTs to guide clini-
cal decision-making. In the absence of clear RCT evidence practi-
tioners must rely on consensus derived clinical practice guidelines,
such as those produced by the Royal College of Obstetricians and
Gynaecologists and the National Institute for Clinical Excellence
(NICE) in the UK (NICE 2004; RCOG 2009), and the Ameri-
can College of Chest Physicians (Bates 2008). The RCOG 2009
guidelines recommend that all women should be assessed in early
pregnancy for risk of VTE, and those assessed as being at high
and persistent risk during pregnancy and after caesarean should
be considered for thromboprophylaxis.
Implications for research
There is a clear need for rigorously conducted large scale RCTs
with sample sizes sufficiently large to assess the effects of meth-
ods of thromboprophylaxis on rare outcomes such as thromboem-
bolic events. Future trials should compare prophylaxis with no
prophylaxis and ideally should use a placebo controlled and fully
blinded design, to minimise the risk of bias if clinicians become
aware of the allocations. No trials have yet assessed non-pharma-
cological methods of thromboprophylaxis during pregnancy and
the postnatal period. The low number of eligible women makes
conducting trials of antenatal thromboprophylaxis extremely chal-
lenging. To achieve an adequate sample size, a trial would need
to be conducted in a very large number of centres, which might
require international collaboration. Trials of prophylaxis after cae-
sarean section are much more feasible, even though the incidence
of TED is lower and the sample size would therefore need to be
even larger (possibly in excess of 10,000). The very high number
of caesarean section operations performedmeans that a trial could
be completed within a relatively short time frame and reasonable
number of centres. Given the difficulties in recruiting women to
trials of prophylaxis for venous TED in pregnancy and the early
postnatal period, if all women being considered for prophylaxis
could be randomised (with appropriate informed consent), the
needed evidence about safety and effectiveness could be obtained
most quickly.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Burrows 2001
Methods Postnatal prophylaxis after caesarean section. Randomisation after surgery. Randomisa-
tion method not stated. Placebo controlled.
Participants 1 centre in Australia. 76 women having elective or emergency caesarean. Exclusions:
history of bleeding disorder; anticoagulant therapy; history of TED; heparin sensitivity;
recent GI haemorrhage or peptic ulcer; hepatic encephalopathy; renal dysfunction re-
quiring dialysis; uncontrolled hypertension.
Interventions LMWH (Dalteparin) or matching placebo (saline) once daily for 4-5 days. Started 4-24
hours after caesarean section.
Outcomes Symptomatic TED.
Symptomatic PE.
Symptomatic DVT.
Blood transfusion.
Bleeding episodes.
Serious wound complications.
Side effects not sufficient to stop treatment.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not stated.
Allocation concealment? Yes Described as “each pack contained pre-
filled syringes containing either dalteparin
or matching placebo”.
Blinding?
Clinicians
Yes See above.
Blinding?
Women
Yes See above.
Blinding?
Outcome Asessors
Yes See above.
Incomplete outcome data addressed?
All outcomes
Yes No losses to follow up after randomisation.
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Casele 2006
Methods Multi centre RCT in 9 centres in the USA. Individual randomisation in blocks.
Participants 120 women recruited.
Inclusion criteria: women requiring thromboprophylaxis in pregnancy (history of blood
clot in leg or lung, history of stroke) aged 18 years or more, who could begin therapy at
< 24 weeks of gestation.
Exclusion criteria: women who were taking heparin because of recurrent pregnancy loss
or women with contraindication to anticoagulants.
Interventions Experimental group (61 women): LMWH (Enoxoparin sodium). Self administered sub-
cutaneous 30 mg twice daily from enrolment until 28 weeks of gestation, then 40 mg
twice daily until delivery.
Control group (59 women): UFH (heparin sodium). Self administered subcutaneous
7500 units twice daily until 28 weeks, then 10,000 units twice daily until delivery.
Baseline bone density test for women in both groups. All women received adjusted
dose coudamin for 6-8 weeks after delivery. All women were asked to take prenatal
vitamins and were asked to take calcium supplements (500 mg) daily from enrolment
until delivery.
Outcomes Bone mass of the proximal femur (measured at baseline and 4 days after delivery) The
power calculationwas based on detecting bonemass changes, the original sample estimate
required was 240.
Notes The study was stopped early, the original power calculation had suggested 240 women
would be required to detect meaningful changes in loss of bone mass between groups.
However, interim analysis suggested that the sample size required would be 1628 and
the study was terminated after 120 women had been recruited over 7 years.
Women were recruited in 9 centres, no information was provided on recruitment in
different centres. It was reported that there was no correlation between bone loss and
institution but it is doubtful that with low recruitment that any institution effects on
any outcomes would be detected.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random number table with each site strat-
ified into blocks of 10.
Allocation concealment? Unclear Not described.
Blinding?
Clinicians
No Not mentioned.
Blinding?
Women
No Not mentioned.
Blinding?
Outcome Asessors
Unclear It was reported that the radiologists carry-
ing out the bone assessments were blind to
group allocation.
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Casele 2006 (Continued)
Incomplete outcome data addressed?
All outcomes
Unclear Some discrepancies in the numbers en-
rolled and outcomes in the 2 published re-
ports. The main study paper used for out-
come data in this review.
120 women randomised. 98 women com-
pleted the study (18% attrition) but of the
22 women who were lost to follow up some
data were available for some outcomes. It
appeared that all women were accounted
for in some of the analysis but not for the
main study outcome.
Therewere somemissingdata formain out-
comes (bone mass) and denominators were
not always clear.
Cornette 2002
Methods RCT individual randomisation.
Participants Setting not clear. Study in Antwerp, Belgium.
44 women with full-term singleton pregnancies admitted for elective caesarean section.
Exclusion criteria: women with known bleeding or coagulation disorders.
Interventions Study looking at the TIMING of LMWH comparing pre and post-operative treatment.
Experimental group: pre-op, 0.3 ml nandroparin calcium (a LMWH) 12 hours before
surgery ( n = 22).
Control group: 0.3 ml (2850 IU) nandroparin calcium 12 hours after surgery (n = 22).
All women received the same fluid regimen before, during and after surgery. Women
were allowed to drink freely 6 hours after surgery.
It was not clear whether participants received any further doses of LMWH after initial
dose.
Outcomes Haemoglobin andhaematocrit concentrations 12hours before and48hours after surgery.
The power calculation was based on changes in haemoglobin levels.
Notes We have not included this study in the analysis as outcomes were not relevant to the the
review.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not described.
Allocation concealment? Unclear “randomly divided in two groups.”
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Cornette 2002 (Continued)
Blinding?
Clinicians
No
Blinding?
Women
No
Blinding?
Outcome Asessors
No
Incomplete outcome data addressed?
All outcomes
Yes No loss to follow up apparent.
Ellison 2001
Methods RCT.
Participants 30 women undergoing caesarean section at risk of thromboembolism.
Interventions Three arm trial.
1. Dalteparin, 5000 IU once daily (10 women).
Enoxaparin 4000 IU once daily (10 women).
3. Tinzaparin 50 IU/kg (based on booking weight) once daily (10 women).
Drugs were administered 6 hours following caesarean and were continued for 5 days.
Outcomes Women were followed up for one day to examine laboratory haemostatic parameters.
Notes Women in this study had blood samples taken in the first 24 hours after caesarean section.
While this study was eligible for inclusion in the review no data relevant to the review’s
primary or secondary outcomes were reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as simple randomisation.
Allocation concealment? Unclear Not described.
Blinding?
Clinicians
No Described as single blind.
Blinding?
Outcome Asessors
No
Incomplete outcome data addressed?
All outcomes
Yes All women seem to be accounted for in the analysis
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Gates 2004a
Methods Pilot study. Multi centre RCT with individual randomisation.
Participants 23 hospitals in the UK (women were recruited in only 8 hospitals).
141 women.
Women undergoing CS where there was clinical uncertainty that thromboprophylaxis
was indicated.
Exclusion criteria: women with a known allergy to heparin.
Interventions Experimental group: once-daily subcutaneous 40 mg enoxoparin (LMWH) in 1ml for
up to 14 days following CS. Given by self injection to start no later than 12 hours after
caesarean delivery.
Control group: once-daily subcutaneous placebo (normal saline 1 ml) for up to 14 days
following CS.
Trial drugs were packaged identically. Duration of treatment and use of other forms
of thromboprophylaxis (eg compression stockings) were at the discretion of attending
clinical staff.
Outcomes Data collection at baseline, at hospital discharge following delivery and at 6 months
postpartum.
Pilot study: main outcome was the number of women recruited.
Clinical outcomes: symptomatic confirmed TED, symptomatic osteoporotic fractures
up to 6 months postpartum.
Secondary outcomes: DVT, PE, thrombosis during period of prophylaxis, blood trans-
fusion, serious wound complications, bleeding, hospital admission, surgical procedures.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes External randomisation.
Allocation concealment? Yes Intervention and identical placebo prepa-
rations dispensed by pharmacy.
Blinding?
Clinicians
Yes Identical packaging of trial drugs. Drugs
provided to study hospitals. Women, clini-
cal staff and investigators were all described
as blind to group allocation.
Blinding?
Women
Yes
Blinding?
Outcome Asessors
Yes
Incomplete outcome data addressed?
All outcomes
Yes Low attrition < 5%. 141 women ran-
domised, data at discharge for 140, and at
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Gates 2004a (Continued)
6 months follow up for 132.
Gates 2004b
Methods Pilot study. Multi centre RCT with individual randomisation.
Participants 23 hospitals in the UK (women were recruited in only 11 hospitals).
16 pregnant women with clinical uncertainty that antenatal thromboprophylaxis was
indicated. Recruitment at all gestational ages.
Inclusion criteria: women with a history of previous thromboembolic events or women
with thrombophilia or another risk factor (all 16 women recruited had had a previous
thromboembolic event).
Exclusion criteria: women with a known allergy to heparin.
Interventions Experimental group: self administered once-daily subcutaneous 40 mg enoxoparin
(LMWH) in 1 ml from antenatal recruitment until 6 weeks after delivery.
Control group: self administered once-daily subcutaneous placebo (normal saline 1 ml)
from antenatal recruitment until 6 weeks after delivery.
Outcomes Data collection at baseline, at hospital discharge following delivery and at 6 months
postpartum.
Outcomes: pilot study: main outcome was the number of women recruited.
Clinical outcomes: symptomatic confirmed TED, symptomatic osteoporotic fractures
up to 6 months postpartum.
Secondary outcomes: DVT, PE, thrombosis during period of prophylaxis, blood trans-
fusion, serious wound complications, bleeding, hospital admission, surgical procedures,
NICU admission for bleeding complications in baby.
Notes Trial drugswere packaged identically. After delivery some clinicians elected todiscontinue
study drugs and 3 women in both groups were given heparin postnatally.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Central telephone randomisation service.
Allocation concealment? Yes Intervention and identical placebo prepa-
rations dispensed by pharmacy.
Blinding?
Clinicians
Yes Identical packaging of trial drugs. Drugs
stored in pharmacy and collected by
women. Women, clinical staff and phar-
macy staff were all described as blind to
group allocation.
Blinding?
Women
Yes
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Gates 2004b (Continued)
Blinding?
Outcome Asessors
Yes
Incomplete outcome data addressed?
All outcomes
Yes Low recruitment to pilot study. All 16
women randomised were followed up until
6 months after delivery. No attrition.
Gibson 1998
Methods Postnatal prophylaxis after caesarean section. Randomisation methods not stated. No
information on blinding - assumed no blinding as drug regimens were different.
Participants 17 women having caesarean section; either emergency or with risk factors for TED.
Interventions UFH 7500 iu every 12 hours; LMWH (enoxaparin) 20 mg or 40 mg once daily. Inter-
vention started after caesarean section; duration of intervention not stated.
Outcomes Symptomatic TED.
Symptomatic PE.
Symptomatic DVT.
Bleeding episodes.
Notes 3-way randomisation (UFH/20 mg enoxaparin/40 mg enoxaparin). 2 enoxaparin groups
combined for the review.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as ’women were randomised’.
Allocation concealment? Unclear Not stated.
Blinding?
Clinicians
No Not feasible.
Blinding?
Women
No Not feasible.
Blinding?
Outcome Asessors
No Not feasible.
Incomplete outcome data addressed?
All outcomes
Unclear No losses to follow up.
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Harenberg 1993
Methods RCT.
Participants 60 pregnant women with no previous indication for thromboprophylaxis.
Interventions 1. UFH, 5000 IU 2 hours prior to delivery (17 women)
2. LMWH 1500 activated partial thromboplastin time units 2 hours before delivery (18
women).
3. No treatment.
Outcomes Maternal blood and umbilical cord blood samples for prothrombin time and coagulation
values.
Notes While this study was eligible for inclusion in the review, the focus of the study was on
blood coagulation parameters and no data relevant to the review’s primary or secondary
outcomes were reported. Data from this study are not included in the analysis.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not described.
Allocation concealment? Unclear Described as “randomized”.
Blinding?
Clinicians
No
Blinding?
Women
No
Blinding?
Outcome Asessors
No
Incomplete outcome data addressed?
All outcomes
Yes No evidence of loss to follow up.
Heilmann 1991
Methods Intrapartum + postnatal prophylaxis after caesarean section. Method of randomisation
not stated. No information on blinding: assumed none as interventions clearly different.
All women were screened for thromboses.
Participants One centre inGermany; 207 women recruited. Eligibility: women delivered by caesarean
section.
Interventions HES 6%, 3 x 500 ml; first 500 ml during the operation, second in the evening of the
day of the operation, third in the evening of the first postoperative day.
UFH 5000 IU 2 hours before the operation and every 8 hours for 7 days.
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Heilmann 1991 (Continued)
Outcomes Asymptomatic TED.
Blood transfusion.
Bleeding episodes.
Serious wound complications.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not stated.
Allocation concealment? Unclear Not stated.
Blinding?
Clinicians
Unclear Not stated.
Blinding?
Women
Unclear Not stated.
Blinding?
Outcome Asessors
Unclear Not stated.
Incomplete outcome data addressed?
All outcomes
Yes No losses to follow up.
Heilmann 2007
Methods RCT (3 arms).
Participants 100 women undergoing caesarean section in 2 treatment arms (50, 50) and 50 additional
matched controls. (Outcome data for the 2 treatment groups only has been included in
this review.)
“The indication for prophylaxis was the previous diagnosis of a heterozygote factor V-
Leiden-mutation.”
Women with uncomplicated pregnancy and “without risk factors for thrombosis” fol-
lowing elective CS.
Interventions Experimental groups:
(1) 50 women LMWH (Dalteparin 5000 IU/daily for 7 days post op, 1st dose 6 hours
post op then every 24 hours).
(2) 50 women UFH (Calciparin 5000 IU twice daily, 1st dose 6 hours post op then
twice daily).
It was not clear if women in either group also received compression stockings.
Control group:
it was not clear that this group was selected randomly, 50 women received compression
stockings but no heparin. Outcome data for this group have not been included in this
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Heilmann 2007 (Continued)
review.
Outcomes DVT.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “The patients were allocated to the treatment group by random-
ization.”
Allocation concealment? Unclear Not described.
Blinding?
Clinicians
Unclear Not mentioned.
Blinding?
Women
Unclear Not mentioned.
Blinding?
Outcome Asessors
Unclear Not mentioned.
Incomplete outcome data addressed?
All outcomes
Yes No loss to follow up apparent.
Hill 1988
Methods Prophylaxis during and after caesarean section. Randomisation by pharmacist not in-
volved in trial. Placebo controlled trial.
Participants One centre in UK; 50 women. Eligibility: women delivered by caesarean section. Exclu-
sions: complications e.g. multiple pregnancy, APH, previous TED.
Interventions UFH 1000 units or saline, 1 hour before operation, then twice daily for 5 days.
Outcomes Symptomatic TED.
Symptomatic DVT.
Symptomatic PE.
Blood transfusion.
Serious wound complications.
Notes
Risk of bias
Item Authors’ judgement Description
26Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hill 1988 (Continued)
Adequate sequence generation? Unclear Not stated.
Allocation concealment? Yes Randomisation by pharmacist not involved
in trial.
Blinding?
Clinicians
Unclear Not stated.
Blinding?
Women
Unclear Not stated.
Blinding?
Outcome Asessors
Unclear Not stated.
Incomplete outcome data addressed?
All outcomes
Yes No losses to follow up.
Howell 1983
Methods Antenatal + intrapartum prophylaxis. Randomisation by sealed envelopes. Recruitment
at time of referral to clinic (8-37 weeks’ gestational age).
Participants One centre in UK. 40 women recruited.
Eligibility: women who had previously had TED treated with anticoagulants for at least
6 weeks.
Interventions Calcium heparin antenatally (10000 IU twice daily) and for 6 weeks postpartum (8000
IU twice daily) or for 6 weeks postpartum only.
Outcomes Symptomatic TED.
Bleeding episodes.
Symptomatic osteoporosis.
Fetal loss.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as “randomised”.
Allocation concealment? Yes Described as “sealed envelope”.
Blinding?
Clinicians
No Not feasible.
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Howell 1983 (Continued)
Blinding?
Women
No Not feasible.
Blinding?
Outcome Asessors
Unclear Not stated.
Incomplete outcome data addressed?
All outcomes
Yes Data could be re-included.
Krauss 1994
Methods RCT.
Participants Setting: university hospital, Gottinghen, Germany.
100 women undergoing CS included in the analysis.
Exclusion: known heparin allergy, gastro-intestinal ulcers, sever kidney, liver or pan-
creatic disease or previous cerebral haemorrhage, severe hypertension (RR > 180/120),
haemorrhagic diathesis.
Interventions Experimental group: 50 women. LMWH (fragmin) once daily 2500 to 5000 anti-Xa
units.
Control group: 50women2-3 times daily 5000 unitsUFH (liquemin) + 500mLDextran
60 during caesarean.
Treatment for 10 days after surgery.
Outcomes Thrombosis and side effects.
Notes Data extraction from translation notes. Original paper in German.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not clear (author confirmed that the allocation to groups was
random).
Allocation concealment? Unclear Not described.
Blinding?
Clinicians
Unclear Not mentioned.
Blinding?
Women
Unclear Not mentioned.
Blinding?
Outcome Asessors
Unclear Not mentioned.
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Krauss 1994 (Continued)
Incomplete outcome data addressed?
All outcomes
Unclear No drop-outs or withdrawals.
Pettila 1999
Methods Antenatal + postnatal prophylaxis. Sealed envelope randomisation. No blinding. 2
women excluded from analysis (withdrawal of consent).
Participants 8 centres in Finland. 107 women recruited. Eligibility: 18 yrs or older, week 0-19 of
gestation, any of: (a) previous PE or VTE above knee before current pregnancy; (b) PE or
VTE during current pregnancy; (c) previous VTE below knee in association with protein
C or protein S deficiency, activated protein C resistance, pregnancy or contraceptive pills.
Interventions Dalteparin (Fragmin) once daily (starting dose 5000 or 7500 IU, dose adjusted based on
anti Xa measurements) or UFH (7500 IU, adjusted according to APTT target values)
twice daily. Treatment started before week 20 of gestation and continued for 6 weeks
after delivery.
Outcomes Symptomatic TED.
Blood transfusion.
Bleeding episodes.
Side effects.
Symptomatic osteoporosis.
Fetal loss.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation “by means of a computer
generated procedure”.
Allocation concealment? Yes “Closed envelope” the randomisation list
was kept outside the centres.
Blinding?
Clinicians
No Open design.
Blinding?
Women
No Open design.
Blinding?
Outcome Asessors
No Open design.
Incomplete outcome data addressed?
All outcomes
Unclear 2 participants lost to follow up after ran-
domisation.
29Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Segal 1975
Methods Very little information on study methods.
RCT - individual randomisation.
Participants Setting: 1973, Jerusalem, Israel.
220 randomised (not clear).
Women identified with varicose veins before delivery (236).
Exclusions: 26 with a history of thrombosis were treated with heparin.
Interventions Experimental group: 116 women.Heparin 50mg (5000 IU) subcutaneous heparin every
12 hours for 4-5 days after delivery (time of initial dose varied, for those having vaginal
delivery about two-thirds had the first dose in active labour (2-3 cm) and a third after
delivery, women having CS the first dose was 2 hrs before).
Control group: 94 women. Care in the comparison group was not described, there did
not seem to be a placebo (routine care/no heparin).
Outcomes Superficial or deep vein thrombosis. Assessment by clinical signs and symptoms by
the investigators (pain, swelling, tenderness, tachycardia, fever). Assessed daily during
treatment and at 6 weeks postpartum.
Notes Very little information on methods was provided. There seemed to be some baseline
imbalance between groups with 16/94 in the control group having a caesarean section
versus 6/116 in the intervention group.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “divided at random.”
Allocation concealment? Unclear No information.
Blinding?
Clinicians
Unclear Not stated.
Blinding?
Women
Unclear Not stated.
Blinding?
Outcome Asessors
Unclear Not clear. There did not seem to be any
placebo, but it was stated that the outcome
assessors were blind to group allocation.
Incomplete outcome data addressed?
All outcomes
Yes All women seem to have been followed up.
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Welti 1981
Methods RCT.
Participants Settingnot clear, authors fromuniversity hospital, obstetric and gynaecology department,
Lausanne, Switzerland.
Study included women undergoing surgery for gynaecological indications. We include
in the analysis 580 women undergoing caesarean section (both emergency and elective).
Interventions Experimental group: 272 women. Physiotherapy and twice daily subcutaneous 5000 IU
heparin (UFH).
Control group: 308 women. Physiotherapy alone (no heparin).
Outcomes Thromboembolic events, bleeding complications.
Notes Data extraction from translation notes and tables in the paper (original paper in French)
.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not stated.
Allocation concealment? Unclear The study was conducted “selon le principle de la randomisation
fermee”.
Blinding?
Clinicians
No There did not appear to be any placebo.
Blinding?
Women
No
Blinding?
Outcome Asessors
No
Incomplete outcome data addressed?
All outcomes
Yes It appeared that all women were followed up.
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APH: antepartum haemorrhage
CS: caesarean section
DVT: deep vein thrombosis
GI: gastrointestinal
IU: international units
LMWH: low molecular weight heparin
NICU: neonatal intensive care unit
PE: pulmonary embolism
RCT: randomised controlled trial
TED: venous thromboembolic disease
UFH: unfractionated heparin
yrs: years
Characteristics of excluded studies [ordered by study ID]
Badawy 2008 The primary focus of this study was on fetal loss and pregnancy outcomes which are covered in other related
Cochrane reviews (Empson 2005; Kaandorp 2009). Pregnant women at least 8 weeks’ gestation with a history
of 3 or more consecutive first trimester pregnancy losses with no known cause after investigation were included
and the intervention group received thromboprophylaxis. Data on DVT and other thromboembolism and the
adverse effects of therapy were also recorded but results were not reported by randomisation group (i.e. for
several outcomes results were only reported for the intervention group, and were therefore difficult to interpret)
.
Blomback 1998 This was not a randomised trial. The study focused on the pharmacokinetic effects of LMWH in pregnant
women that had had a previous thromboembolic event.
Brenner 2005 (The LIVE-ENOX study.) The primary focus of this trial was on recurrent pregnancy loss in women with
thrombophilia, and most outcomes relate to pregnancy outcomes (prevention of miscarriage). Women in both
arms of the trial received LMWH; the purpose of the study was to compare different dosing regimes (single
versus twice daily doses of 40 mg LMWH). Prevention of miscarriage is the focus of related Cochrane reviews
(Empson 2005; Kaandorp 2009).
Chistolini 2006 (Abstract.) Study of women with recurrent pregnancy loss.
De Vries 2005 Trial registration/ongoing study examining pregnancy and neonatal outcomes in women with a history of
uteroplacental insufficiency (with or without known thrombophilia). Women known to be at high risk of
thromboembolism (i.e. that had any previous history of thromboembolism) were explicitly excluded.
Dendrinos 2007 This study focuses on recurrent pregnancy loss which is covered in related Cochrane reviews (Empson 2005;
Kaandorp 2009).
Farquharson 2002 This study focuses on recurrent pregnancy loss which is covered in related Cochrane reviews (Empson 2005;
Kaandorp 2009).
Kutteh 1996a Allocation to this trial was not random; first 25 women allocated to one arm, next 25 to other arm.
Kutteh 1996b Allocation to this trial was not random; alternate allocation.
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(Continued)
Middeldorp 2005 This study focused on recurrent miscarriage, not on women at increased risk of thromboembolism; women that
had had a previous thromboembolism were explicitly excluded.
Noble 2005 This was not a RCT.
Rai 1997 This study focuses on recurrent pregnancy loss which is covered in related Cochrane reviews (Empson 2005;
Kaandorp 2009).
Rey 2009 The primary focus of this study was on the prevention of serious obstetric complications (pre-eclampsia and fetal
loss). All women recruited had had a serious adverse event in a previous pregnancy (e.g. miscarriage). Women at
high risk of thromoboembolism (e.g. with known thrombophilia or that had had a previous thromboembolic
event) were specifically excluded and no outcomes for thromboembolism were reported.
Stephenson 2004 This study focused on the prevention of miscarriage; all women recruited to the study had a history of recurrent
pregnancy loss and the primary outcome was live birth.
Thaler 2004 (Brief abstract.) Study focusing on placental blood flow and pregnancy outcomes.
Tulppala 1997 This study recruited women after recurrent miscarriage with no known cause, not on women at increased risk
of TED.
DVT: deep venous thrombosis
LMWH: low molecular weight heparin
RCT: randomised controlled trial
TED: venous thromboembolic disease
Characteristics of studies awaiting assessment [ordered by study ID]
De Veciana 2001
Methods RCT.
Participants Pregnant women; no further details.
Interventions Dalteparin (n = 61) versus UFH (n = 60).
Outcomes No TED occurred.
Notes Reported as abstract only; awaiting full publication.
Dittmer 1991
Methods RCT.
Participants 100 women undergoing caesarean section.
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Dittmer 1991 (Continued)
Interventions LMWH versus UFH.
Outcomes DVT, allergic reactions, bleeding.
Notes Reported as abstract only; awaiting full publication.
Hamersley 1998
Methods Antenatal prophylaxis. Method of randomisation not stated. No information on blinding; assumed no blinding as
interventions have different administration regimens.
Participants One centre in USA. 61 women recruited. Eligibility: women with antiphospholipid syndrome, protein S or protein
C deficiency or idiopathic thrombophilia.
Interventions LMWH or UFH. Dose adjusted to maintain ani-Xa level between 0.03 and 0.05 IU/ml. Duration of therapy and
timing and number of injections not stated. Daily 81 mg aspirin given to both groups.
Outcomes Symptomatic TED.
Thrombocytopenia.
Notes Assumed to be antenatal prophylaxis - not stated. Published as abstract only - author contacted but no response.
Kamin 2008
Methods Brief abstract in German. Awaiting translation and publication of full study report.
Participants
Interventions
Outcomes
Notes
DVT: deep vein thrombosis
IU: international units
LMWH: low molecular weight heparin
RCT: randomised controlled trial
TED: venous thromboembolic disease
UFH: unfractionated heparin
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Characteristics of ongoing studies [ordered by study ID]
STOP CLOT
Trial name or title STOP CLOT: study of LMWH in high risk postpartum women following caesarean section.
Methods RCT (randomised, double-blind, placebo-controlled study).
Participants Women at moderate to high risk for VTE following caesarean section. Aim to recruit 134 women.
Interventions LMWH (4500 IU tinzaparin sodium) versus placebo once daily for 3-7 days postpartum.
Outcomes Event rate of DVT (asymptomatic) on day of hospital discharge. Secondary outcomes symptomatic DVT
and PE, death, major and minor bleeding in 6 weeks’ postpartum.
Starting date 2002
Contact information Marc Rodger, Ottawa Hospital, Ottawa, Onatrio, Canada.
Notes Contact author contacted 26.03.09. No response to date.
TIPPS
Trial name or title TIPPS (Thrombophilia in pregnancy prophylaxis study).
Methods RCT with a series of add-on studies in different participating centres. Stratified randomisation in permuted
blocks prepared by trial statistician. Central randomisation using numbered, sealed, opaque envelopes.
Participants Women with thrombophilia, placenta-related pregnancy complications or at high risk of thromboembolism.
The numbers of women included in different add on studies varied across centres.
Interventions Intervention: subcutaneous LMWH (Dalteparin sodium) 5000 IU daily until 20 weeks’ gestation, then 5000
IU twice daily until the onset of labour (at the discretion of women or clinical staff ).
Control: no antenatal treatment.
Women in both groups received 5000 IU LMWH daily after delivery until 6 weeks postpartum
Outcomes Range of outcomes in different add-on studies. Including bone density, coagulation activity and pregnancy
outcomes.
Starting date July 2000 (some findings of the study have now been published).
Contact information Dr Marc Rodger, The Ottawa Hospital, Canada.
Notes We contacted the lead investigator on 15th June 2009 for more information on the study.
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DVT: deep vein thrombosis
IU: international units
LMWH: low molecular weight heparin
PE: pulmonary embolism
RCT: randomised controlled trial
TED: venous thromboembolic disease
VTE: venous thromboembolism
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D A T A A N D A N A L Y S E S
Comparison 1. Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal death 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2 Symptomatic thromboembolic
events
2 56 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.04, 2.99]
2.1 UFH 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.72]
2.2 LMWH 1 16 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.02, 7.14]
3 Symptomatic pulmonary
embolism
1 16 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.02, 7.14]
3.1 LMWH 1 16 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.02, 7.14]
4 Symptomatic deep vein
thrombosis
1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.72]
4.1 UFH 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.72]
5 Asymptomatic thromboembolic
events
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Blood transfusion 1 16 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6.1 LMWH 1 16 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7 Bleeding episodes 1 40 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.26, 98.00]
7.1 UFH 1 40 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.26, 98.00]
7.2 LMWH 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8 Serious wound complications 1 16 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8.1 LMWH 1 16 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9 Side effects sufficient to stop
treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10 Side effects not sufficient to
stop treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
11 Symptomatic osteoporosis 2 56 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 69.52]
11.1 UFH 1 40 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 69.52]
11.2 LMWH 1 16 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
12 Fetal loss 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.90]
12.1 UFH 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.90]
12.2 LMWH 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
13 Thrombocytopenia 1 16 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.14, 64.26]
13.1 LMWH 1 16 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.14, 64.26]
14 Fetal anomalies 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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Comparison 2. Antenatal prophylaxis: LMWH versus UFH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal death 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2 Symptomatic thromboembolic
events
2 178 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.09, 2.49]
3 Symptomatic pulmonary
embolism
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4 Symptomatic deep vein
thrombosis
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5 Asymptomatic thromboembolic
events
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Blood transfusion 1 105 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.01, 4.47]
7 Bleeding episodes 0 0 Risk Ratio (M-H, Random, 95% CI) Not estimable
8 Serious wound complications 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9 Side effects sufficient to stop
treatment
1 105 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.01, 4.47]
10 Side effects not sufficient to
stop treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
11 Symptomatic osteoporosis 2 188 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.11, 4.18]
12 Fetal loss 2 222 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.21, 1.77]
13 Thrombocytopenia 1 105 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
14 Fetal anomalies 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 3. Caesarean section: LMWH or UFH versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal death 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2 Symptomatic thromboembolic
events
4 840 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.39, 4.27]
2.1 LMWH 2 210 Risk Ratio (M-H, Fixed, 95% CI) 2.97 [0.31, 28.03]
2.2 UFH 2 630 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.19, 3.76]
3 Symptomatic pulmonary
embolism
3 764 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.25, 4.87]
3.1 UFH 2 630 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.13, 4.48]
3.2 LMWH 1 134 Risk Ratio (M-H, Fixed, 95% CI) 3.09 [0.13, 74.51]
4 Symptomatic deep vein
thrombosis
3 706 Risk Ratio (M-H, Fixed, 95% CI) 1.74 [0.23, 13.31]
4.1 LMWH 1 76 Risk Ratio (M-H, Fixed, 95% CI) 2.85 [0.12, 67.83]
4.2 UFH 2 630 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.07, 18.02]
5 Asymptomatic thromboembolic
events
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Blood transfusion 3 266 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.03, 2.13]
6.1 LMWH 2 216 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.54]
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6.2 UFH 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.2 [0.01, 3.97]
7 Bleeding episodes 3 796 Risk Ratio (M-H, Fixed, 95% CI) 5.15 [2.64, 10.05]
7.1 LMWH 2 216 Risk Ratio (M-H, Fixed, 95% CI) 6.17 [0.76, 49.96]
7.2 UFHH 1 580 Risk Ratio (M-H, Fixed, 95% CI) 5.03 [2.49, 10.18]
8 Serious wound complications 3 266 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.07, 16.13]
8.1 LMWH 2 216 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.07, 16.13]
8.2 UFH 1 50 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9 Side effects sufficient to stop
treatment
1 140 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9.1 LMWH 1 140 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10 Side effects not sufficient to
stop treatment
1 76 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10.1 LMWH 1 76 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 4. Caesarean section: LMWH versus UFH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal death 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2 Symptomatic thromboembolic
events
3 217 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.99]
3 Symptomatic pulmonary
embolism
1 17 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4 Symptomatic deep vein
thrombosis
3 217 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.99]
5 Asymptomatic thromboembolic
events
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Blood transfusion 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7 Bleeding episodes 1 17 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8 Serious wound complications 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9 Side effects sufficient to stop
treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10 Side effects not sufficient to
stop treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 5. Caesarean section: HES versus UFH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maternal death 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2 Symptomatic thromboembolic
events
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3 Symptomatic pulmonary
embolism
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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4 Symptomatic deep vein
thrombosis
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5 Asymptomatic thromboembolic
events
1 207 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.30, 2.03]
6 Blood transfusion 1 207 Risk Ratio (M-H, Fixed, 95% CI) 2.02 [0.19, 21.93]
7 Bleeding episodes 1 207 Risk Ratio (M-H, Fixed, 95% CI) 2.52 [0.50, 12.72]
8 Serious wound complications 1 207 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [0.56, 4.10]
9 Side effects sufficient to stop
treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10 Side effects not sufficient to
stop treatment
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 6. Postnatal prophylaxis (including vaginal deliveries and by CS). Heparin versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic VTE events 1 210 Risk Ratio (M-H, Fixed, 95% CI) 0.16 [0.02, 1.36]
2 Pulmonary embolism 1 210 Risk Ratio (M-H, Fixed, 95% CI) 0.16 [0.01, 3.34]
3 Deep vein thrombosis 1 210 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.03, 2.55]
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Analysis 1.2. Comparison 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo,
Outcome 2 Symptomatic thromboembolic events.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo
Outcome: 2 Symptomatic thromboembolic events
Study or subgroup Heparin No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 UFH
Howell 1983 0/20 1/20 50.0 % 0.33 [ 0.01, 7.72 ]
Subtotal (95% CI) 20 20 50.0 % 0.33 [ 0.01, 7.72 ]
Total events: 0 (Heparin), 1 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 LMWH
Gates 2004b 0/8 1/8 50.0 % 0.33 [ 0.02, 7.14 ]
Subtotal (95% CI) 8 8 50.0 % 0.33 [ 0.02, 7.14 ]
Total events: 0 (Heparin), 1 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 28 28 100.0 % 0.33 [ 0.04, 2.99 ]
Total events: 0 (Heparin), 2 (No treatment)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
0.1 0.2 0.5 1 2 5 10
Favours heparin Favours no treatment
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Analysis 1.3. Comparison 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo,
Outcome 3 Symptomatic pulmonary embolism.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo
Outcome: 3 Symptomatic pulmonary embolism
Study or subgroup Heparin No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LMWH
Gates 2004b 0/8 1/8 100.0 % 0.33 [ 0.02, 7.14 ]
Total (95% CI) 8 8 100.0 % 0.33 [ 0.02, 7.14 ]
Total events: 0 (Heparin), 1 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
0.1 0.2 0.5 1 2 5 10
Favours heparin Favours no treatment
Analysis 1.4. Comparison 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo,
Outcome 4 Symptomatic deep vein thrombosis.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo
Outcome: 4 Symptomatic deep vein thrombosis
Study or subgroup Heparin No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 UFH
Howell 1983 0/20 1/20 100.0 % 0.33 [ 0.01, 7.72 ]
Total (95% CI) 20 20 100.0 % 0.33 [ 0.01, 7.72 ]
Total events: 0 (Heparin), 1 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
0.1 0.2 0.5 1 2 5 10
Favours heparin Favours no treatment
42Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.6. Comparison 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo,
Outcome 6 Blood transfusion.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo
Outcome: 6 Blood transfusion
Study or subgroup Heparin No treatment Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LMWH
Gates 2004b 0/8 0/8 0.0 [ 0.0, 0.0 ]
Total (95% CI) 8 8 0.0 [ 0.0, 0.0 ]
Total events: 0 (Heparin), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours heparin Favours no treatment
Analysis 1.7. Comparison 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo,
Outcome 7 Bleeding episodes.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo
Outcome: 7 Bleeding episodes
Study or subgroup Heparin No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 UFH
Howell 1983 2/20 0/20 100.0 % 5.00 [ 0.26, 98.00 ]
Subtotal (95% CI) 20 20 100.0 % 5.00 [ 0.26, 98.00 ]
Total events: 2 (Heparin), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
2 LMWH
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Heparin), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Favours heparin Favours no treatment
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(. . . Continued)
Study or subgroup Heparin No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total (95% CI) 20 20 100.0 % 5.00 [ 0.26, 98.00 ]
Total events: 2 (Heparin), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
0.1 0.2 0.5 1 2 5 10
Favours heparin Favours no treatment
Analysis 1.8. Comparison 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo,
Outcome 8 Serious wound complications.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo
Outcome: 8 Serious wound complications
Study or subgroup UF heparin No treatment Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LMWH
Gates 2004b 0/8 0/8 0.0 [ 0.0, 0.0 ]
Total (95% CI) 8 8 0.0 [ 0.0, 0.0 ]
Total events: 0 (UF heparin), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.11. Comparison 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo,
Outcome 11 Symptomatic osteoporosis.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo
Outcome: 11 Symptomatic osteoporosis
Study or subgroup Heparin No treatment Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 UFH
Howell 1983 1/20 0/20 3.00 [ 0.13, 69.52 ]
Subtotal (95% CI) 20 20 3.00 [ 0.13, 69.52 ]
Total events: 1 (Heparin), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 LMWH
Gates 2004b 0/8 0/8 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 8 8 0.0 [ 0.0, 0.0 ]
Total events: 0 (Heparin), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 28 28 3.00 [ 0.13, 69.52 ]
Total events: 1 (Heparin), 0 (No treatment)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
0.1 0.2 0.5 1 2 5 10
Favours heparin Favours no treatment
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Analysis 1.12. Comparison 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo,
Outcome 12 Fetal loss.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo
Outcome: 12 Fetal loss
Study or subgroup Heparin No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 UFH
Howell 1983 1/20 1/20 100.0 % 1.00 [ 0.07, 14.90 ]
Subtotal (95% CI) 20 20 100.0 % 1.00 [ 0.07, 14.90 ]
Total events: 1 (Heparin), 1 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 LMWH
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Heparin), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 20 20 100.0 % 1.00 [ 0.07, 14.90 ]
Total events: 1 (Heparin), 1 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
0.1 0.2 0.5 1 2 5 10
Favours heparin Favours no treatment
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Analysis 1.13. Comparison 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo,
Outcome 13 Thrombocytopenia.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 1 Antenatal prophylaxis: UF or LMW heparin versus no treatment or placebo
Outcome: 13 Thrombocytopenia
Study or subgroup Heparin No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LMWH
Gates 2004b 1/8 0/8 100.0 % 3.00 [ 0.14, 64.26 ]
Total (95% CI) 8 8 100.0 % 3.00 [ 0.14, 64.26 ]
Total events: 1 (Heparin), 0 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
0.1 0.2 0.5 1 2 5 10
Favours heparin Favours no treatment
Analysis 2.2. Comparison 2 Antenatal prophylaxis: LMWH versus UFH, Outcome 2 Symptomatic
thromboembolic events.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 2 Antenatal prophylaxis: LMWH versus UFH
Outcome: 2 Symptomatic thromboembolic events
Study or subgroup LMW heparin UF heparin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Casele 2006 2/60 4/57 0.48 [ 0.09, 2.49 ]
Pettila 1999 0/32 0/29 0.0 [ 0.0, 0.0 ]
Total (95% CI) 92 86 0.48 [ 0.09, 2.49 ]
Total events: 2 (LMW heparin), 4 (UF heparin)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
0.1 0.2 0.5 1 2 5 10
Favours LMW heparin Favours UF heparin
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Analysis 2.6. Comparison 2 Antenatal prophylaxis: LMWH versus UFH, Outcome 6 Blood transfusion.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 2 Antenatal prophylaxis: LMWH versus UFH
Outcome: 6 Blood transfusion
Study or subgroup LMW heparin UF heparin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pettila 1999 0/50 2/55 100.0 % 0.22 [ 0.01, 4.47 ]
Total (95% CI) 50 55 100.0 % 0.22 [ 0.01, 4.47 ]
Total events: 0 (LMW heparin), 2 (UF heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
0.1 0.2 0.5 1 2 5 10
Favours LMW heparin Favours UF heparin
Analysis 2.9. Comparison 2 Antenatal prophylaxis: LMWH versus UFH, Outcome 9 Side effects sufficient
to stop treatment.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 2 Antenatal prophylaxis: LMWH versus UFH
Outcome: 9 Side effects sufficient to stop treatment
Study or subgroup LMW heparin UF heparin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pettila 1999 0/50 2/55 100.0 % 0.22 [ 0.01, 4.47 ]
Total (95% CI) 50 55 100.0 % 0.22 [ 0.01, 4.47 ]
Total events: 0 (LMW heparin), 2 (UF heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
0.1 0.2 0.5 1 2 5 10
Favours LMW heparin Favours UF heparin
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Analysis 2.11. Comparison 2 Antenatal prophylaxis: LMWH versus UFH, Outcome 11 Symptomatic
osteoporosis.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 2 Antenatal prophylaxis: LMWH versus UFH
Outcome: 11 Symptomatic osteoporosis
Study or subgroup LMW heparin UF heparin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Casele 2006 1/43 0/40 17.8 % 2.80 [ 0.12, 66.70 ]
Pettila 1999 0/50 2/55 82.2 % 0.22 [ 0.01, 4.47 ]
Total (95% CI) 93 95 100.0 % 0.68 [ 0.11, 4.18 ]
Total events: 1 (LMW heparin), 2 (UF heparin)
Heterogeneity: Chi2 = 1.30, df = 1 (P = 0.25); I2 =23%
Test for overall effect: Z = 0.42 (P = 0.68)
0.1 0.2 0.5 1 2 5 10
Favours LMW heparin Favours UF heparin
Analysis 2.12. Comparison 2 Antenatal prophylaxis: LMWH versus UFH, Outcome 12 Fetal loss.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 2 Antenatal prophylaxis: LMWH versus UFH
Outcome: 12 Fetal loss
Study or subgroup LMW heparin UF heparin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Casele 2006 4/60 7/57 88.3 % 0.54 [ 0.17, 1.76 ]
Pettila 1999 1/50 1/55 11.7 % 1.10 [ 0.07, 17.12 ]
Total (95% CI) 110 112 100.0 % 0.61 [ 0.21, 1.77 ]
Total events: 5 (LMW heparin), 8 (UF heparin)
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
0.1 0.2 0.5 1 2 5 10
Favours LMW heparin Favours UF heparin
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Analysis 2.13. Comparison 2 Antenatal prophylaxis: LMWH versus UFH, Outcome 13 Thrombocytopenia.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 2 Antenatal prophylaxis: LMWH versus UFH
Outcome: 13 Thrombocytopenia
Study or subgroup LMW heparin UF heparin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pettila 1999 0/50 0/55 0.0 [ 0.0, 0.0 ]
Total (95% CI) 50 55 0.0 [ 0.0, 0.0 ]
Total events: 0 (LMW heparin), 0 (UF heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 3.2. Comparison 3 Caesarean section: LMWH or UFH versus placebo, Outcome 2 Symptomatic
thromboembolic events.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 3 Caesarean section: LMWH or UFH versus placebo
Outcome: 2 Symptomatic thromboembolic events
Study or subgroup Heparin Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LMWH
Burrows 2001 1/39 0/37 2.85 [ 0.12, 67.83 ]
Gates 2004a 1/66 0/68 3.09 [ 0.13, 74.51 ]
Subtotal (95% CI) 105 105 2.97 [ 0.31, 28.03 ]
Total events: 2 (Heparin), 0 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
2 UFH
Hill 1988 0/25 0/25 0.0 [ 0.0, 0.0 ]
Welti 1981 3/272 4/308 0.85 [ 0.19, 3.76 ]
Subtotal (95% CI) 297 333 0.85 [ 0.19, 3.76 ]
0.1 0.2 0.5 1 2 5 10
Favours heparin Favours placebo
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(. . . Continued)
Study or subgroup Heparin Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 3 (Heparin), 4 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
Total (95% CI) 402 438 1.30 [ 0.39, 4.27 ]
Total events: 5 (Heparin), 4 (Placebo)
Heterogeneity: Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
0.1 0.2 0.5 1 2 5 10
Favours heparin Favours placebo
Analysis 3.3. Comparison 3 Caesarean section: LMWH or UFH versus placebo, Outcome 3 Symptomatic
pulmonary embolism.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 3 Caesarean section: LMWH or UFH versus placebo
Outcome: 3 Symptomatic pulmonary embolism
Study or subgroup Heparin Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 UFH
Hill 1988 0/25 0/25 0.0 [ 0.0, 0.0 ]
Welti 1981 2/272 3/308 0.75 [ 0.13, 4.48 ]
Subtotal (95% CI) 297 333 0.75 [ 0.13, 4.48 ]
Total events: 2 (Heparin), 3 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
2 LMWH
Gates 2004a 1/66 0/68 3.09 [ 0.13, 74.51 ]
Subtotal (95% CI) 66 68 3.09 [ 0.13, 74.51 ]
Total events: 1 (Heparin), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 363 401 1.10 [ 0.25, 4.87 ]
Total events: 3 (Heparin), 3 (Placebo)
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
0.1 0.2 0.5 1 2 5 10
Favours heparin Favours placebo
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Analysis 3.4. Comparison 3 Caesarean section: LMWH or UFH versus placebo, Outcome 4 Symptomatic
deep vein thrombosis.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 3 Caesarean section: LMWH or UFH versus placebo
Outcome: 4 Symptomatic deep vein thrombosis
Study or subgroup Heparin Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LMWH
Burrows 2001 1/39 0/37 2.85 [ 0.12, 67.83 ]
Subtotal (95% CI) 39 37 2.85 [ 0.12, 67.83 ]
Total events: 1 (Heparin), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
2 UFH
Hill 1988 0/25 0/25 0.0 [ 0.0, 0.0 ]
Welti 1981 1/272 1/308 1.13 [ 0.07, 18.02 ]
Subtotal (95% CI) 297 333 1.13 [ 0.07, 18.02 ]
Total events: 1 (Heparin), 1 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 336 370 1.74 [ 0.23, 13.31 ]
Total events: 2 (Heparin), 1 (Placebo)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.59)
0.1 0.2 0.5 1 2 5 10
Favours heparin Favours placebo
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Analysis 3.6. Comparison 3 Caesarean section: LMWH or UFH versus placebo, Outcome 6 Blood
transfusion.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 3 Caesarean section: LMWH or UFH versus placebo
Outcome: 6 Blood transfusion
Study or subgroup Heparin Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LMWH
Burrows 2001 0/39 1/37 0.32 [ 0.01, 7.54 ]
Gates 2004a 0/69 0/71 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 108 108 0.32 [ 0.01, 7.54 ]
Total events: 0 (Heparin), 1 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
2 UFH
Hill 1988 0/25 2/25 0.20 [ 0.01, 3.97 ]
Subtotal (95% CI) 25 25 0.20 [ 0.01, 3.97 ]
Total events: 0 (Heparin), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Total (95% CI) 133 133 0.24 [ 0.03, 2.13 ]
Total events: 0 (Heparin), 3 (Placebo)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
0.1 0.2 0.5 1 2 5 10
Favours heparin Favours placebo
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Analysis 3.7. Comparison 3 Caesarean section: LMWH or UFH versus placebo, Outcome 7 Bleeding
episodes.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 3 Caesarean section: LMWH or UFH versus placebo
Outcome: 7 Bleeding episodes
Study or subgroup Heparin Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LMWH
Burrows 2001 0/39 0/37 0.0 [ 0.0, 0.0 ]
Gates 2004a 6/69 1/71 6.17 [ 0.76, 49.96 ]
Subtotal (95% CI) 108 108 6.17 [ 0.76, 49.96 ]
Total events: 6 (Heparin), 1 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.088)
2 UFHH
Welti 1981 40/272 9/308 5.03 [ 2.49, 10.18 ]
Subtotal (95% CI) 272 308 5.03 [ 2.49, 10.18 ]
Total events: 40 (Heparin), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.50 (P < 0.00001)
Total (95% CI) 380 416 5.15 [ 2.64, 10.05 ]
Total events: 46 (Heparin), 10 (Placebo)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 4.81 (P < 0.00001)
0.002 0.1 1 10 500
Favours heparin Favours placebo
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Analysis 3.8. Comparison 3 Caesarean section: LMWH or UFH versus placebo, Outcome 8 Serious wound
complications.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 3 Caesarean section: LMWH or UFH versus placebo
Outcome: 8 Serious wound complications
Study or subgroup Heparin Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LMWH
Burrows 2001 0/39 0/37 0.0 [ 0.0, 0.0 ]
Gates 2004a 1/69 1/71 1.03 [ 0.07, 16.13 ]
Subtotal (95% CI) 108 108 1.03 [ 0.07, 16.13 ]
Total events: 1 (Heparin), 1 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
2 UFH
Hill 1988 0/25 0/25 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 25 25 0.0 [ 0.0, 0.0 ]
Total events: 0 (Heparin), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 133 133 1.03 [ 0.07, 16.13 ]
Total events: 1 (Heparin), 1 (Placebo)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
0.1 0.2 0.5 1 2 5 10
Favours heparin Favours placebo
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Analysis 3.9. Comparison 3 Caesarean section: LMWH or UFH versus placebo, Outcome 9 Side effects
sufficient to stop treatment.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 3 Caesarean section: LMWH or UFH versus placebo
Outcome: 9 Side effects sufficient to stop treatment
Study or subgroup Heparin Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LMWH
Gates 2004a 0/69 0/71 0.0 [ 0.0, 0.0 ]
Total (95% CI) 69 71 0.0 [ 0.0, 0.0 ]
Total events: 0 (Heparin), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 3.10. Comparison 3 Caesarean section: LMWH or UFH versus placebo, Outcome 10 Side effects
not sufficient to stop treatment.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 3 Caesarean section: LMWH or UFH versus placebo
Outcome: 10 Side effects not sufficient to stop treatment
Study or subgroup Heparin Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LMWH
Burrows 2001 0/39 0/37 0.0 [ 0.0, 0.0 ]
Total (95% CI) 39 37 0.0 [ 0.0, 0.0 ]
Total events: 0 (Heparin), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 4.2. Comparison 4 Caesarean section: LMWH versus UFH, Outcome 2 Symptomatic
thromboembolic events.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 4 Caesarean section: LMWH versus UFH
Outcome: 2 Symptomatic thromboembolic events
Study or subgroup LMW heparin UF heparin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gibson 1998 0/11 0/6 0.0 [ 0.0, 0.0 ]
Heilmann 2007 0/50 1/50 0.33 [ 0.01, 7.99 ]
Krauss 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Total (95% CI) 111 106 0.33 [ 0.01, 7.99 ]
Total events: 0 (LMW heparin), 1 (UF heparin)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
0.1 0.2 0.5 1 2 5 10
Favours LMH heparin Favours UF heparin
Analysis 4.3. Comparison 4 Caesarean section: LMWH versus UFH, Outcome 3 Symptomatic pulmonary
embolism.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 4 Caesarean section: LMWH versus UFH
Outcome: 3 Symptomatic pulmonary embolism
Study or subgroup LMW heparin UF heparin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gibson 1998 0/11 0/6 0.0 [ 0.0, 0.0 ]
Total (95% CI) 11 6 0.0 [ 0.0, 0.0 ]
Total events: 0 (LMW heparin), 0 (UF heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 4.4. Comparison 4 Caesarean section: LMWH versus UFH, Outcome 4 Symptomatic deep vein
thrombosis.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 4 Caesarean section: LMWH versus UFH
Outcome: 4 Symptomatic deep vein thrombosis
Study or subgroup LMW heparin UF heparin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gibson 1998 0/11 0/6 0.0 [ 0.0, 0.0 ]
Heilmann 2007 0/50 1/50 0.33 [ 0.01, 7.99 ]
Krauss 1994 0/50 0/50 0.0 [ 0.0, 0.0 ]
Total (95% CI) 111 106 0.33 [ 0.01, 7.99 ]
Total events: 0 (LMW heparin), 1 (UF heparin)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
0.1 0.2 0.5 1 2 5 10
Favours LMW heparin Favours UF heparin
Analysis 4.7. Comparison 4 Caesarean section: LMWH versus UFH, Outcome 7 Bleeding episodes.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 4 Caesarean section: LMWH versus UFH
Outcome: 7 Bleeding episodes
Study or subgroup LMW heparin UF heparin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gibson 1998 0/11 0/6 0.0 [ 0.0, 0.0 ]
Total (95% CI) 11 6 0.0 [ 0.0, 0.0 ]
Total events: 0 (LMW heparin), 0 (UF heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
58Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.5. Comparison 5 Caesarean section: HES versus UFH, Outcome 5 Asymptomatic
thromboembolic events.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 5 Caesarean section: HES versus UFH
Outcome: 5 Asymptomatic thromboembolic events
Study or subgroup HES UF heparin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heilmann 1991 7/103 9/104 100.0 % 0.79 [ 0.30, 2.03 ]
Total (95% CI) 103 104 100.0 % 0.79 [ 0.30, 2.03 ]
Total events: 7 (HES), 9 (UF heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
0.1 0.2 0.5 1 2 5 10
Favours HES Favours UF heparin
Analysis 5.6. Comparison 5 Caesarean section: HES versus UFH, Outcome 6 Blood transfusion.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 5 Caesarean section: HES versus UFH
Outcome: 6 Blood transfusion
Study or subgroup HES UF heparin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heilmann 1991 2/103 1/104 100.0 % 2.02 [ 0.19, 21.93 ]
Total (95% CI) 103 104 100.0 % 2.02 [ 0.19, 21.93 ]
Total events: 2 (HES), 1 (UF heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
0.1 0.2 0.5 1 2 5 10
Favours HES Favours UF heparin
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Analysis 5.7. Comparison 5 Caesarean section: HES versus UFH, Outcome 7 Bleeding episodes.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 5 Caesarean section: HES versus UFH
Outcome: 7 Bleeding episodes
Study or subgroup HES UF heparin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heilmann 1991 5/103 2/104 100.0 % 2.52 [ 0.50, 12.72 ]
Total (95% CI) 103 104 100.0 % 2.52 [ 0.50, 12.72 ]
Total events: 5 (HES), 2 (UF heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
0.1 0.2 0.5 1 2 5 10
Favours HES Favours UF heparin
Analysis 5.8. Comparison 5 Caesarean section: HES versus UFH, Outcome 8 Serious wound complications.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 5 Caesarean section: HES versus UFH
Outcome: 8 Serious wound complications
Study or subgroup HES UF heparin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heilmann 1991 9/103 6/104 100.0 % 1.51 [ 0.56, 4.10 ]
Total (95% CI) 103 104 100.0 % 1.51 [ 0.56, 4.10 ]
Total events: 9 (HES), 6 (UF heparin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
0.1 0.2 0.5 1 2 5 10
Favours HES Favours UF heparin
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Analysis 6.1. Comparison 6 Postnatal prophylaxis (including vaginal deliveries and by CS). Heparin versus
no treatment, Outcome 1 Symptomatic VTE events.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 6 Postnatal prophylaxis (including vaginal deliveries and by CS). Heparin versus no treatment
Outcome: 1 Symptomatic VTE events
Study or subgroup Heparin No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Segal 1975 1/116 5/94 100.0 % 0.16 [ 0.02, 1.36 ]
Total (95% CI) 116 94 100.0 % 0.16 [ 0.02, 1.36 ]
Total events: 1 (Heparin), 5 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.094)
0.01 0.1 1 10 100
Favours heparin Favours no treatment
Analysis 6.2. Comparison 6 Postnatal prophylaxis (including vaginal deliveries and by CS). Heparin versus
no treatment, Outcome 2 Pulmonary embolism.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 6 Postnatal prophylaxis (including vaginal deliveries and by CS). Heparin versus no treatment
Outcome: 2 Pulmonary embolism
Study or subgroup Heparin No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Segal 1975 0/116 2/94 100.0 % 0.16 [ 0.01, 3.34 ]
Total (95% CI) 116 94 100.0 % 0.16 [ 0.01, 3.34 ]
Total events: 0 (Heparin), 2 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
0.01 0.1 1 10 100
Favours heparin Favours no treatment
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Analysis 6.3. Comparison 6 Postnatal prophylaxis (including vaginal deliveries and by CS). Heparin versus
no treatment, Outcome 3 Deep vein thrombosis.
Review: Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period
Comparison: 6 Postnatal prophylaxis (including vaginal deliveries and by CS). Heparin versus no treatment
Outcome: 3 Deep vein thrombosis
Study or subgroup Heparin No treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Segal 1975 1/116 3/94 100.0 % 0.27 [ 0.03, 2.55 ]
Total (95% CI) 116 94 100.0 % 0.27 [ 0.03, 2.55 ]
Total events: 1 (Heparin), 3 (No treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
0.01 0.1 1 10 100
Favours heparin Favours no treatment
F E E D B A C K
Cundiff, July 2007
Summary
The guidelines for anticoagulation during pregnancy and post partum by the American College of Chest Physicians [1] and the Royal
College of Obstetricians and Gynaecologists[ 2] are arguably the standard for care in the USA and UK, respectively. Despite the lack
of evidence from randomised trials, these opinion-based guidelines recommend anticoagulants in many instances, and they can be
referenced in medico-legal cases.
This review appropriately concludes that anticoagulant thromboprophylaxis during pregnancy is not supported by evidence that it
is safe and effective. Since anticoagulation carries risks of bleeding, osteoporosis, and fetal deformity, the appropriate implication for
practice would be that thromboprophylaxis with anticoagulants should not be used outside of a randomised trial. The implications for
research should state that any randomised trial of anticoagulation conducted in pregnant women should be placebo-controlled.
1. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: The Seventh ACCP Conference on
Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(3 Suppl):627S-644.
2. Royal College of Obstetricians and Gynaecologists (RCOG). Thromboprophylaxis during pregnancy, labour and after vaginal
delivery. London (UK): Royal College of Obstetricians and Gynaecologists; 2004 (Guideline no. 37).
(Summary of comment from David K Cundiff, July 2007)
Reply
Thanks for these comments. We accept that there remains a need for further randomised trials looking at thromboprophylaxis in
pregnant women; as the lack of blinding in previous studies has meant that results are difficult to interpret ideally trials should be
placebo-controlled although the use of placebo may not always be practicable or ethical. We acknowledge that anticoagulation carries
risk of bleeding, and several related Cochrane reviews provide evidence of this. However, reviews which examine thromboprophylaxis in
non-pregnant groups at risk of thromboembolism may not be relevant during pregnancy, as the physiological mechanisms controlling
blood coagulation are altered, and the risks of thromboembolic disease and side effects may be different.
In this review, we did not have sufficient evidence from trials to assess the harms and benefits associated with the use of anticoagulants,
or with different types of anticoagulant. In the absence of evidence from trials, guidelines based on a range of evidence have been used
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to underpin clinical practice. While we do not believe it is appropriate for this review to make recommendations about what such
guidelines should say, we note under Implications for research, that if all pregnant women being considered for thromboprophylaxis were
entered into randomised trials (with appropriate consent) this would help to obtain the needed evidence about safety and effectiveness
as quickly as possible.
Contributors
Reply to feedback prepared by Rebecca Tooher and Therese Dowswell.
WH A T ’ S N E W
Last assessed as up-to-date: 26 November 2009.
26 June 2009 New search has been performed Search updated. Data from seven new trials have been
included (Casele 2006; Gates 2004a; Gates 2004b;
Heilmann 2007; Krauss 1994; Segal 1975; Welti 1981)
(including two trials that were ongoing in the previous
version of the review). Eleven new studies considered for
inclusion have been excluded, and two new trials are still
ongoing. One trial which was previously included has
now been excluded (Rai 1997). While there is now more
evidence on some of the review’s outcomes, themain con-
clusions remain unaltered.
The authors have replied toFeedback received fromDavid
Cundiff.
26 June 2009 New citation required but conclusions have not changed New authors prepared this update.
H I S T O R Y
Protocol first published: Issue 3, 1999
Review first published: Issue 2, 2002
3 January 2008 Amended Converted to new review format.
12 November 2007 Feedback has been incorporated Feedback from David Cundiff added.
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C O N T R I B U T I O N S O F A U T H O R S
In this updated version of the review, all four review authors assessed study eligibility. R Tooher (RT) and T Dowswell (TD) carried
out data extraction. TD entered data and RT checked data. All four authors contributed to the text of the review and commented on
drafts.
D E C L A R A T I O N S O F I N T E R E S T
Simon Gates and Lucy-Jane Davis were involved in the conduct of two studies included in this review (Gates 2004a; Gates 2004b);
the other review authors assessed these studies.
S O U R C E S O F S U P P O R T
Internal sources
• The University of Liverpool, UK.
External sources
• National Institute for Health Research, UK.
NIHR NHS Cochrane Collaboration Programme Grant Scheme award for NHS-prioritised centrally-managed, pregnancy and
childbirth systematic reviews: CPGS02
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In this updated version of the review the background and methods section have been updated.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Postpartum Period; Pregnancy Complications, Hematologic [∗prevention & control]; Randomized Controlled Trials as Topic; Venous
Thrombosis [∗prevention & control]
MeSH check words
Female; Humans; Pregnancy
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